James Featherstone, Ph.D. is a Practice Leader, Product Development and Commercialization Practice, EU, for Quintiles Consulting. He joined Quintiles from Wood Mackenzie, a business intelligence and strategy consulting services company based in the UK where he was the global head of consulting for the pharmaceuticals and biotechnology practice. Dr. Featherstone was hired in 2000 to build the high-value life sciences strategic consulting practice, defining the overall strategy and executing growth in the European and U.S. markets. Previously, he was with the pharmaceutical division of British Petroleum (BP), where he focused on strategic outsourcing opportunities with pharma companies. Prior to BP, he was a technical consultant with Promega Corporation, a biotech firm. Dr. Featherstone has a Ph.D. and conducted postdoctoral research on genetic mechanisms underlying embryological patterning and development. He also holds a BSc (Hons) in Microbiology.

Daryl Gaugler is the President of Innovex. He brings more than 20 years of pharmaceutical sales and senior management experience to the position. Mr. Gaugler oversees the U.S. commercial business for Innovex Americas with operations in the United States, Canada and Mexico and with service offerings that include investment-based commercial partnerships, fee-based outsourcing and health-management services. Most recently, Mr. Gaugler established the NovaQuest Commercial Unit within the Quintiles Partnering group as the premier provider of commercial co-promotion partnerships, and has served on the executive teams of both NovaQuest and Innovex. As a founder of the U.S.-based outsourcing unit, Mr. Gaugler has built more than 100 field sales teams in six years with Innovex, establishing 12 new commercial companies and Launching 41 new products. Prior to joining Innovex, Mr. Gaugler entered the outsourcing arena with MMD as a regional sales director. He also spent numerous years with Bristol-Myers Squibb. Mr. Gaugler holds a B.S. degree from Shippensburg University.

Mark Archer has held a series of progressively more senior roles in sales, marketing, general management and strategy. At Innovex, Mr. Archer heads up a team of global business developers who work alongside customers—whether international pharma companies or smaller biotech firms—to develop international commercial solutions for their brands, integrating market access and patient outcomes services as required. He lived and worked in France for 10 years while at sanofi-aventis.

Jacco Keja, Ph.D. is a Practice Leader, Market Access, EU, for Qintiles Consulting. He joined Quintiles Consulting in 2007 as Practice Leader, Market Access. Previously, Dr. Keja was responsible for building Organon's global and local competence in strategic and operational pricing, as well as expanding health economics and outcomes research. He built and organized these corporate groups and directed much of the underlying process changes needed to focus Organon on pricing and reimbursement.

Dr. Keja earned his Ph.D. in biology (neurophysiology) at Vrije Universiteit (VU) in Amsterdam, while also studying pharmacy in Utrecht, Netherlands. He earned his undergraduate degree in biology and a Master's in Medical Biology in Utrecht. He is also a visiting professor in pricing at the Erasmus University-affiliated Institute of Life Sciences Business Economics.

Ed Silverman is a prize-winning journalist who has covered the pharmaceutical industry for 14 years during a long career as a business writer. He recently joined Elsevier Business Intelligence, which publishes The Pink Sheet, In Vivo and other publications, as a bureau chief. Prior to that, he founded and ran the Pharmalot blog for The Star-Ledger of New Jersey, and worked at New York Newsday and Investor’s Business Daily, among other newspapers. Silverman has a master’s degree in journalism from New York University and a bachelor’s degree in accounting from Binghamton University.